SCHEMBL8552490

SCHEMBL8552490

COC(=O)C(Cc1ccccc1)N1C(=O)CC1SCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
PKM P14618 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ACE P12821 1/20 0.42
GAA P10253 1/20 0.41
RECQL P46063 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
POLB P06746 1/20 0.38
GFER P55789 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8557349 0.91 L3MBTL1 (0.40) ALDH1A1NPC1RAB9AACECYP2C9
SCHEMBL8552273 0.90 ACE (0.37) ALDH1A1PKMNPC1RAB9AACE
SCHEMBL8550015 0.88 ACE (0.38) ALDH1A1ACEGAAMEN1KMT2A
SCHEMBL8557133 0.86 ACE (0.37) ALDH1A1ACECYP2C9POLB
SCHEMBL8554773 0.86 ALDH1A1 (0.54) ALDH1A1PKMACEGAARECQL
SCHEMBL8551020 0.85 ACE (0.43) ALDH1A1ACEMEN1KMT2ACYP2C9
SCHEMBL5170081 0.83 GAA (0.42) ALDH1A1NPC1RAB9AACEGAA
SCHEMBL27484036 0.81 ACE (0.40) ALDH1A1ACEMEN1KMT2A
SCHEMBL8551199 0.80 ALDH1A1 (0.43) ALDH1A1PKMACEGAARECQL
SCHEMBL5167607 0.79 GAA (0.44) ALDH1A1NPC1ACEGAARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0840725-A1 AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1998-05-13 EP disclosed
WO-1997002242-A1 AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1997-01-23 WO disclosed